王齡玉 / Ling-Yu Wang
職稱： 副教授
現職： 長庚大學
電話： 3989
學歷： 美國加州大學戴維斯分校博士
專長領域： 癌症生物學
個人網頁： https://pure.lib.cgu.edu.tw/zh/persons/ling-yu-wang-2
研究方向及研究室特色
研究方向及研究室特色：
表觀遺傳調控是除 DNA 序列變異之外，導致腫瘤細胞基因表現異常的重要機制，常伴隨全域性轉錄圖譜的改變。近年研究亦指出，細胞代謝除維持生物合成、能量平衡與細胞生理功能外，亦深度參與表觀遺傳調控。由於癌細胞普遍呈現代謝異常與表觀遺傳標記改變，釐清兩者間的調控機制為癌症生物學的重要課題。
前列腺癌為男性第二常見癌症，其臨床治療的主要瓶頸在於晚期對標靶藥物產生抗藥性。其中，癌細胞發生譜系轉分化（lineage transdifferentiation）尤為棘手；當腫瘤轉變為神經內分泌前列腺癌（NEPC）時，將呈現高度惡性且缺乏有效標靶治療。
本實驗室致力於探討表觀遺傳因子與細胞代謝如何影響前列腺癌之染色質狀態與基因表現，進而驅動譜系轉分化與抗藥性。同時，本實驗室亦在新興藥物型態—蛋白降解劑之開發與其應用於晚期前列腺癌治療方面取得重要成果，期望為創新癌症治療策略奠定分子基礎。
研究重點包括:
· 細胞譜系轉化之基因調控與轉錄體分析
· 細胞譜系轉化之表觀遺傳調控與轉錄因子順反體分析
· 蛋白降解劑的作用模式與治療抗藥性前列腺癌的潛力
· 細胞代謝與表觀遺傳調控的關聯
AWARD
第二十屆國家新創獎-學研新創獎: 治療去勢抗性前列腺癌的蛋白質降解靶向藥物開發PUBLICATION
PUBLICATIONS
1. ADDIN EN.REFLIST Hung CL, Hsu WN, Wang TC, Chen WR, Chen YT, Kuo ZK, Hu TL, Lin YC, Yeh HH, Lin HC, Yu CJ, Fu CW, Liu HH, Hsu HC, Lin PH, Pang ST, Lai CH, Wang LY#. 2026. Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer. Neoplasia 71:101253.
2. Wang LY*#, Hung CL, Wang TC, Hsu HC, Kung HJ, Lin KH. 2025. PROTACs as Therapeutic Modalities for Drug Discovery in Castration-Resistant Prostate Cancer. Annu Rev Pharmacol Toxicol 65:375-396.
3. Hung CL, Liu HH, Fu CW, Yeh HH, Hu TL, Kuo ZK, Lin YC, Jhang MR, Hwang CS, Hsu HC, Kung HJ, Wang LY#. 2023. Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer. EBioMedicine 90:104500.
4. Hung CL, Wang LY#, Fu CW, Hsu HC, Kung H-J. 2023. Abstract LB133: An orally bioavailable degrader targeting androgen receptor and the splice variant in castration resistant prostate cancer. Cancer Research 83:LB133-LB133.
5. Bui NN, Li CY, Wang LY, Chen YA, Kao WH, Chou LF, Hsieh JT, Lin H, Lai CH. 2023. Clostridium scindens metabolites trigger prostate cancer progression through androgen receptor signaling. J Microbiol Immunol Infect 56:246-256.
6. Liu JS, Fang WK, Yang SM, Wu MC, Chen TJ, Chen CM, Lin TY, Liu KL, Wu CM, Chen YC, Chuu CP, Wang LY, Hsieh HP, Kung HJ, Wang WC. 2022. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer. J Biomed Sci 29:29.
7. Wang HJ, Pochampalli M, Wang LY*, Zou JX, Li PS, Hsu SC, Wang BJ, Huang SH, Yang P, Yang JC, Chu CY, Hsieh CL, Sung SY, Li CF, Tepper CG, Ann DK, Gao AC, Evans CP, Izumiya Y, Chuu CP, Wang WC, Chen HW, Kung HJ. 2019. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene 38:17-32.
8. Shih JW, Chiang WF, Wu ATH, Wu MH, Wang LY, Yu YL, Hung YW, Wang WC, Chu CY, Hung CL, Changou CA, Yen Y, Kung HJ. 2017. Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1alpha co-activator driving oral cancer progression. Nat Commun 8:15874.
9. Wang LY*, Hung CL, Chen YR, Yang JC, Wang J, Campbell M, Izumiya Y, Chen HW, Wang WC, Ann DK, Kung HJ. 2016. KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis. Cell Rep 16:3016-3027.
10. Wang J, Wang H, Wang LY, Cai D, Duan Z, Zhang Y, Chen P, Zou JX, Xu J, Chen X, Kung HJ, Chen HW. 2016. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death Differ 23:1886-1896.
11. Shih JW, Wang LY, Hung CL, Kung HJ, Hsieh CL. 2015. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism. Int J Mol Sci 16:28943-28978.
12. Hung CL, Wang LY*, Yu YL, Chen HW, Srivastava S, Petrovics G, Kung HJ. 2014. A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci USA 111:18697-18702.
13. Chu CH, Wang LY*, Hsu KC, Chen CC, Cheng HH, Wang SM, Wu CM, Chen TJ, Li LT, Liu R, Hung CL, Yang JM, Kung HJ, Wang WC. 2014. KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor. J Med Chem 57:5975-5985.
14. Wang LY*, Kung HJ. 2012. Male germ cell-associated kinase is overexpressed in prostate cancer cells and causes mitotic defects via deregulation of APC/CCDH1. Oncogene 31:2907-2918.
15. Wu Z, Chang PC, Yang JC, Chu CY, Wang LY, Chen NT, Ma AH, Desai SJ, Lo SH, Evans CP, Lam KS, Kung HJ. 2010. Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer 1:40-49.
16. Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, Gandour-Edwards R, deVere White RW, Kung HJ. 2008. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. Oncogene 27:499-505.
17. Wang LY*, Shiozaki K. 2006. The fission yeast stress MAPK cascade regulates the pmp3+ gene that encodes a highly conserved plasma membrane protein. FEBS Lett 580:2409-2413.
18. Wang LY*, Shimada K, Morishita M, Shiozaki K. 2005. Response of fission yeast to toxic cations involves cooperative action of the stress-activated protein kinase Spc1/Sty1 and the Hal4 protein kinase. Mol Cell Biol 25:3945-3955.
19. Lin SJ, Wang LY, Huang YJ, Kuo ML. 2001. Effect of interleukin (IL)-12 and IL-15 on apoptosis and proliferation of umbilical cord blood mononuclear cells. Bone Marrow Transplant 28:439-445.
20. Ghosh P, Qui Y, Wang LY, Kung HJ. Tyrosine kinome profiling: oncogenic mutations and therapeutic targeting in cancer. Molecular Oncology: Causes of Cancer and Targets for Treatment. ISBN: 9780521876629. Editors: Gelmann E, Sawyers C, and Rauscher III F. Cambridge University Press. 2014.
21. Wang LY*, Guo W, Kim K, Pochampalli M, Hung CL, Izumiya Y, Kung HJ. Histone demethylases in prostate cancer. Nuclear Signaling Pathways and Targeting Transcription in Cancer. ISBN: 978-1-4614-8039-6. Editor: Rakesh Kumar. Springer. 2013.
* First and co-first author
# Corresponding author